Multidrug-resistant Acinetobacter baumannii infection in children
Maia De Luca1, Giulia Angelino, Francesca Ippolita Calò Carducci
1University Department of Pediatrics, Ospedale Pediatrico Bambino Gesù, Rome, Italy. maiadeluca@gmail.com
BMJ Case Reports
|June 13, 2012
Summary
A young AIDS patient with brain toxoplasmosis and multidrug-resistant Acinetobacter baumannii sepsis was successfully treated with colistin and tigecycline. This case highlights effective treatment options for complex bacterial infections in immunocompromised individuals.
Area of Science:
- Infectious Diseases
- Microbiology
- Critical Care Medicine
Background:
- Acinetobacter baumannii is a significant cause of hospital-acquired infections.
- Multidrug-resistant (MDR) strains pose a growing therapeutic challenge.
- Patients with Acinetobacter baumannii infections often have underlying conditions, such as Acquired Immunodeficiency Syndrome (AIDS).
Observation:
- A young patient diagnosed with AIDS presented with concurrent brain toxoplasmosis and sepsis.
- The sepsis was caused by a multidrug-resistant strain of Acinetobacter baumannii.
- Standard antibiotic therapies were likely to be ineffective due to the resistance profile.
Findings:
- The patient's multidrug-resistant Acinetobacter baumannii sepsis was successfully treated with a combination of colistin and tigecycline.
- This dual therapy demonstrated efficacy against a highly resistant bacterial pathogen.
- The treatment regimen was well-tolerated by the immunocompromised patient.
Implications:
- Colistin and tigecycline represent viable therapeutic options for severe infections caused by MDR Acinetobacter baumannii.
- Effective management of MDR bacterial infections is crucial in immunocompromised populations.
- Further research into treatment strategies for MDR pathogens in vulnerable patient groups is warranted.
Related Concept Videos
01:25Mechanism of Antibiotic Resistance in MRSA
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
01:25Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...